How should we use convalescent plasma therapies for the management of COVID-19?
Convalescent plasma (CP) from blood donors with antibodies to severe acute respiratory syndrome coronavirus 2 may benefit patients with COVID-19 by providing immediate passive immunity via transfusion or by being used to manufacture hyperimmune immunoglobulin preparations. Optimal product characteri...
| 主要な著者: | , , |
|---|---|
| フォーマット: | Journal article |
| 言語: | English |
| 出版事項: |
American Society of Hematology
2020
|